PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31931920-18	2020	In the base-case economic analysis, using list prices only, the cost-effectiveness comparison of lenvatinib versus BSC yields an incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained of $65,872, and the comparison of sorafenib versus BSC yields an ICER of $85,644 per QALY gained.	lenvatinib	97-107	solute carrier family 12 member 2	Homo sapiens	269-272